Skip to main content

Table 1 Baseline demographics and spirometry (safety set)

From: A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

  Glycopyrronium 50 μg o.d. (N = 327) Tiotropium 18 μg o.d. (N = 330)
Mean (SD) age, years 63.2 (7.9) 63.7 (8.0)
Male, n (%) 237 (72.5) 248 (75.2)
Ethnicity, n (%)   
   Caucasian 225 (68.8) 232 (70.3)
   Black 0 0
   Asian 95 (29.1) 91 (27.6)
   Native American 6 (1.8) 7 (2.1)
   Other 1 (0.3) 0
Severity of COPD (GOLD 2010), n (%)   
   Mild 0 1 (0.3)
   Moderate 191 (58.4) 193 (58.5)
   Severe 136 (41.6) 136 (41.2)
Mean (SD) duration of COPD, years 6.5 (5.1) 6.2 (5.1)
Baseline COPD exacerbation history*, n (%)   
   0 exacerbations 255 (78.0) 247 (74.8)
   1 exacerbation 52 (15.9) 61 (18.5)
   ≥2 exacerbations 20 (6.1) 22 (6.7)
ICS use at baseline, n (%) 163 (49.8) 174 (52.7)
Smoking history, n (%)   
   Ex-smoker 179 (54.7) 182 (55.2)
   Current smoker 148 (45.3) 148 (44.8)
Mean (SD) duration of smoking, pack-years 39.6 (20.4) 40.2 (21.5)
Mean (SD) FEV1 post-bronchodilator, L 1.5 (0.5) 1.5 (0.5)
Mean (SD) post-bronchodilator FEV1% predicted 53.2 (13.1) 53.9 (12.7)
Mean (SD) post-bronchodilator FEV1 reversibility, % 17.9 (13.5) 17.6 (13.6)
Mean (SD) post-bronchodilator FEV1/FVC, % 47.4 (10.7) 47.2 (10.5)
  1. Pack-years = total years of smoking multiplied by cigarette packs smoked per day; *In the year prior to screening; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; SD = standard deviation; o.d. = once-daily.